MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
RadNet Interest Expense 2011-2026 | RDNT
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense RadNet
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.9 M | 6.35 M | -1.83 M | -1.44 M | -120 K | -1.28 M | 181 K | 258 K | 21 K | 34 K | 60 K | 86 K | 245 K | 381 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.9 M | -1.83 M | 1.99 M |
Quarterly Interest Expense RadNet
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.04 M | 7.76 M | - | 5.41 M | 7.9 M | - | 4.08 M | -40 K | -1.43 M | - | -1.4 M | 7 K | -165 K | - | 167 K | -1.66 M | -206 K | - | 139 K | 115 K | -6 K | - | -2 K | -1.27 M | - | - | -7 K | -5 K | -1 K | - | -4 K | -7 K | 247 K | - | -174 K | -4 K | -2 K | - | -8 K | -413 K | 3 K | - | -6 K | 4 K | -2 K | - | -4 K | -150 K | 2 K | - | 1.36 M | 1.34 M | 1.15 M | - | 1.51 M | 689 K | 1.87 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.04 M | -1.66 M | 853 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Danaher Corporation
DHR
|
-56 M | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
20.3 M | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 11.38 | 6.36 % | $ 323 M |  Israel |
 |
IQVIA Holdings
IQV
|
670 M | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
NeoGenomics
NEO
|
-379 K | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 99.74 | -0.18 % | $ 3.93 B | USA |
 |
National Research Corporation
NRC
|
862 K | $ 18.77 | 0.64 % | $ 461 M | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.12 | - | $ 99.5 K | USA |
 |
Precipio
PRPO
|
-1 K | $ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Personalis
PSNL
|
24 K | $ 7.96 | -0.13 % | $ 472 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 46.3 | 0.02 % | $ 1.86 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
Thermo Fisher Scientific
TMO
|
12 M | $ 579.45 | -0.69 % | $ 221 B | USA |
 |
Trinity Biotech plc
TRIB
|
6.75 M | $ 0.79 | -3.54 % | $ 61.9 M |  Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 173.53 | -1.12 % | $ 19.3 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 6.8 | 1.19 % | $ 882 M | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 31.72 | -1.34 % | $ 1.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 182.22 | -0.43 % | $ 15 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 66.55 | -0.91 % | $ 4.61 B | USA |